| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0004 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0004 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | THZ-2-102-1 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0005 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0005 |